Lannett Drug Patent Portfolio
Lannett owns 1 orange book drug protected by 1 US patent Given below is the list of Lannett's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6344215 | Methylphenidate modified release formulations | 27 Oct, 2020 | Expired |
Lannett's Family Patents
Recent FDA approvals and tentative approvals for Lannett
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Selexipag |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 23 Dec, 2025 |
| Omeprazole |
SUPPL-15
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Manufacturing (CMC) | 24 Mar, 2005 |
Lannett Drug List
Given below is the complete list of Lannett's drugs and the patents protecting them.
1. Metadate Cd
Metadate Cd is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6344215 | Methylphenidate modified release formulations |
27 Oct, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metadate Cd's drug page